Browsed by
Tag: Appoints

Nitro Appoints New CFO and CMO to Accelerate Growth of Document Productivity Platform

Nitro Appoints New CFO and CMO to Accelerate Growth of Document Productivity Platform

Former BlueVine and Imperva executives join global leadership team at Nitro Software

Nitro Software (ASX: NTO), a global document productivity company, today announced the expansion of its executive leadership team with the appointment of Ana Sirbu as Chief Financial Officer (CFO) and Maria Robinson as the company’s first Chief Marketing Officer (CMO).

“We’re thrilled to welcome two world-class leaders to the Nitro executive team. We’re excited to gain Ana’s deep financial expertise and strong growth and commercial acumen, as well as Maria’s invaluable SaaS experience and proven track record driving customer acquisition,” said Sam Chandler, founder and CEO of Nitro.

Sirbu most recently served as CFO of BlueVine, a fintech startup providing a leading banking platform specifically designed for small businesses. She fueled the company’s rapid growth and spearheaded its capital markets strategy leading them through three equity funding rounds and raising over $800 million in debt and equity financing. Prior to BlueVine, Sirbu was a technology investor at Capital G, Google’s growth investing arm, and at Silver Lake Partners. She was named one of the Top 25 Women Leaders in Financial Technology in 2020 and was recognized by the Women in Fintech Powerlist in 2017.

“It is an exciting time to join Nitro and drive together with the team our customers’ journey of productivity software adoption and use. It is a privilege to join a global company so focused on its customers’ experience and driving value for its customers, especially in the current economic climate. I look forward to working with the team to further drive the growth of our business and to provide even more value to our customers and shareholders,” said Sirbu.

Robinson is a Silicon Valley native, with more than 20 years of experience successfully building and scaling teams through innovative use of digital, data-driven, growth

Read the rest
Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific …

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific …

VANCOUVER, British Columbia, Oct. 09, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Mark Swaim, a former practicing physician and researcher has joined the Algernon Medical and Scientific Advisory Board.

Dr. Mark Swaim, MD, PhD graduated from Duke University with honours, where he was an NIH-sponsored Medical Scientist Training Program scholar, and was elected to the Alpha Omega Alpha Honor Medical Society and served as its president. He completed post-graduate training in internal medicine, gastroenterology and hepatology at Duke University Medical Center and post-doctoral research at National Taiwan University in Taipei. Dr. Swaim served on the faculties of Duke University Medical Center, University of Texas MD Anderson Cancer Center and the McGovern Medical School of University of Texas in Houston. He was elected to fellowship in the American College of Physicians. He is editor-in-chief and founder of  BioPub.co a small-cap biotech special situations investing website with a global following.

Update on South Korea COVID Trial

Due to a lack of sufficiently ill patients, which is a direct result of a highly-successful government initiated pandemic mitigation strategy, the Company has decided to close the investigator-led South Korea trial. Instead, the Company will remain focused on its Phase 2b/3 multinational Ifenprodil COVID study, which currently has enrolled more than 75% of its target enrollment.

The Company has projected that the multinational Phase 2b/3 study will be completed in November 2020, with a planned data readout before the end of Q4, 2020.

“I am very pleased that Dr. Swaim has accepted our invitation to join our Advisory Board and we look forward to working closely with him,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We also look forward to reaching

Read the rest
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer

Greg Patrick to Retire as Chief Financial Officer

ROCKVILLE, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the appointment of James Kelly as Chief Financial Officer, effective October 12, 2020. Mr. Kelly brings to Supernus over 25 years of biopharmaceutical industry experience, including most recently as Chief Financial Officer and Treasurer of Vanda Pharmaceuticals Inc. Mr. Kelly will be responsible for developing and leading Supernus’ financial operations and strategy to effectively support the Company’s growth. Greg Patrick, who will be retiring from his role as Supernus’ Chief Financial Officer, will remain an advisor to the Company to assist with the transition.

“Jim brings to Supernus a proven track record of financial leadership experience, including nearly 10 years as chief financial officer of a public biopharmaceutical company,” said Jack Khattar, President and CEO of Supernus. “Jim’s financial and business expertise will be invaluable as we advance our company forward. We are thrilled to have him join us at such an exciting time.”

Mr. Kelly is a highly qualified biopharmaceutical executive who brings strong skills and experience in the financial stewardship of publicly-traded companies, development and commercialization of pharmaceutical products, execution and management of strategic transactions and collaborations and significant capital markets experience funding growth companies. Most recently, Mr. Kelly was the Chief Financial Officer of Vanda Pharmaceuticals, a public biopharmaceutical company from 2010 to 2020. Prior to joining Vanda, Mr. Kelly was Vice President, Controller at Medimmune, a biotechnology subsidiary of the AstraZeneca Group, where he managed global financial accounting and reporting. He joined MedImmune as Director of Sales and Marketing Finance in 2006. Prior to MedImmune and beginning in 2000, Mr.

Read the rest
ZEDRA Creates New Global Head of Funds Role, Appoints Wim Ritz

ZEDRA Creates New Global Head of Funds Role, Appoints Wim Ritz

In a move designed to signal the next stage of its strategic ambition to develop a strong international fund administration business, ZEDRA has appointed Wim Ritz to the newly created role of global head of funds. Wim will be based at ZEDRA’s offices in Luxembourg.

The creation of the new global role highlights ZEDRA’s commitment to drive company growth by developing and investing in its funds administration services. The Group has established teams in Jersey and Guernsey, where a strong focus exists for ESG products, and a major presence in Cayman and Singapore as well.

Initially trained as a lawyer, Wim has built up a wealth of experience over 25 years and has a strong track record in leadership and business growth. He has worked across all areas of the private funds industry, specialising in real estate and private equity and is a leading professional in the market.

Commenting on his appointment, Wim noted that “ZEDRA has a fresh, entrepreneurial approach to fund administration, which is exactly what the industry needs. I will be aiming to build on ZEDRA’s reputation for its personalised service and innovative approach. Within the Group, there is already a pedigree and reputation for excellence, backed by award winning teams in our Cayman office, for example, where we have a strong reputation amongst international private, institutional and sovereign clients to build on.”

Wim started his career as a lawyer working with private equity and real estate clients, before heading TMF’s real estate and private equity teams in Luxembourg. His most recent role was as country managing director for Vistra, leading the rapid growth of its fund administration business.

Welcoming Wim, ZEDRA’s CEO, Ivo Hemelraad says, “Wim brings a proven set of skills and experience to this new role. Our objective is to be recognised as a

Read the rest
CrystalGenomics Appoints Gavin Choy, as President, CG Pharmaceuticals, Inc. to Lead Pipeline Expansion and Global Operations

CrystalGenomics Appoints Gavin Choy, as President, CG Pharmaceuticals, Inc. to Lead Pipeline Expansion and Global Operations

SEOUL, South Korea, Oct. 7, 2020 /PRNewswire/ — CrystalGenomics, Inc. (KOSDAQ: 083790), a commercial stage biopharmaceutical company that is dedicated to the discovery, development and commercialization of novel therapeutics in unmet medical need areas of inflammation, oncology, and infectious disease, today announced the appointment of Gavin Choy, PharmD, MBA as President of CG Pharmaceuticals, Inc., CrystalGenomics’ subsidiary focused on the clinical development of novel therapeutics. Dr. Choy most recently served as Chief Operating Officer at Apollomics, Inc.

“As a senior leader in multiple prior biotech companies and a scientific or operational advisor of several others, Gavin has extensive experience in leading biotech innovation from early stage research through commercialization of therapies. His significant insights will be invaluable to CrystalGenomics as we advance our pipeline assets for the potential treatment of a broad range of diseases and seek additional assets to develop,” said Dr. Joong Myung Cho, Chairman, CG Pharmaceuticals and CrystalGenomics.

Gavin Choy, PharmD, MBA

Dr. Choy brings to CrystalGenomics a proven track record in drug development and global development operations. He has led cross functional teams in areas of clinical research, development operations, biometrics, pharmacovigilance, project and alliance management, medical writing, field liaisons, clinical pharmacology, IT, legal, and public relations in therapeutic areas of infectious disease, hematology and oncology, immuno-oncology, and vaccines. Through design and leading the formation of high-performing teams, Dr. Choy has built successful global organizations leading to the advancement of pipeline assets, multiple INDs and commercialized drug products. Dr. Choy has designed corporate strategies leading to successful financings and instrumental in in-licensing opportunities at prior organizations. Dr. Choy received a doctorate in pharmacy from the University of Southern California, completed post-doctorate training at the Department of Veteran Affairs, and holds a Health Care focused Master of Business Administration from the Paul Merage School of Business, University

Read the rest